More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each
year for the treatment of lymphoma, leukemia, immune-deficiency illnesses, congenital …

Graft-versus-host disease (GVHD) is a common cause of morbidity and mortality after
allogeneic hematopoietic stem cell transplantation. Systemic findings involving the skin …

Mesenchymal stem cells (MSCs) inhibit the proliferation of HLA-unrelated T lymphocytes to
allogeneic stimulation, but the mechanisms responsible for this activity are not fully …

Preliminary studies using directed-donor ex vivo expanded human mesenchymal stem cells
(hMSCs) have shown promise in the treatment of acute graft-versus-host disease (aGVHD) …

Patients with steroid‐resistant acute graft versus host disease (aGVHD) have a dismal
prognosis, with mortality rates in excess of 90%. We sought to identify a subgroup of patients …

Allogeneic hematopoietic SCT (HSCT) is an established treatment for some children with life-
threatening hematological disease, immune deficiencies and inborn errors of metabolism …

Chronic graft-versus-host disease (GVHD) is a major limitation of successful allogeneic
hematopoietic stem cell transplantation (HSCT). Extracorporeal photochemotherapy (ECP) …

Kidney disease frequently complicates malignancy and its treatment. The spectrum of
disease in this setting includes acute renal failure (ARF), chronic renal failure, and tubular …

Graft-versus-host disease is a common complication following allogeneic hematopoetic
stem cell transplantation that can affect multiple organ systems, including the eyes. Ocular …

Background Parenteral nutrition (PN) is still widely preferred to enteral nutrition (EN) in
malnourished patients undergoing allogeneic stem-cell transplantation (allo-SCT) after …